Stockscreener 앱 받기
0.00
100.00%
-3.41
시간 외 거래:
3.41
3.41
+
전일 마감가:
$3.41
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$524.82M
수익:
$117.10K
순이익/손실:
$-161.61M
주가수익비율:
0.00
EPS:
-2.4059
순현금흐름:
-
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$6.30
Opthea Limited Adr Stock (OPT) Company Profile
OPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OPT
Opthea Limited Adr
|
0.00 | 524.82M | 117.10K | -161.61M | 0 | -2.4059 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Opthea Limited Adr Stock (OPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-03-25 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2025-03-25 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-03-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-12-08 | 개시 | H.C. Wainwright | Buy |
| 2022-04-26 | 개시 | SVB Leerink | Outperform |
| 2020-11-17 | 개시 | Citigroup | Buy |
| 2020-11-11 | 개시 | Oppenheimer | Outperform |
| 2020-11-11 | 개시 | SVB Leerink | Outperform |
| 2020-11-11 | 개시 | Truist | Buy |
모두보기
Opthea Limited Adr 주식(OPT)의 최신 뉴스
Opthea (NASDAQ:OPT) Stock Price Up 7.2% – What’s Next? - Defense World
Opthea Limited Depositary Receipt Stock Analysis and ForecastHigh-octane gains - jammulinksnews.com
Opthea (NASDAQ:OPT) Stock Price Up 7.2% – Time to Buy? - Defense World
Opthea Limited Relocates Registered Office to Melbourne - TipRanks
Millennium Management LLC Reduces Stock Holdings in Opthea Limited (NASDAQ:OPT) - Defense World
Citadel Advisors LLC Takes $79,000 Position in Opthea Limited (NASDAQ:OPT) - Defense World
Opthea Limited (NASDAQ:OPT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Arcellx Inc (ACLX) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail
Opthea Limited (NASDAQ:OPT) Given Average Rating of “Hold” by Analysts - Defense World
Sarepta Therapeutics (SRPT) Gets a Buy from Oppenheimer - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ) - The Globe and Mail
Brokerages Set Opthea Limited (NASDAQ:OPT) PT at $1.33 - Defense World
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Opthea Ltd shares corporate update in SEC filing - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Opthea Announces Termination of ShORe and COAST Trials of Sozinibercept - HCPLive
Opthea Halts Wet AMD Clinical Trials By Investing.com - Investing.com South Africa
Opthea Halts Wet AMD Clinical Trials - Investing.com
Opthea Limited (NASDAQ:OPT) Receives $1.33 Consensus PT from Brokerages - Defense World
Hold Rating Issued for Opthea Limited Amid Uncertainty Following Phase 3 Trial Failure - TipRanks
Opthea Limited: Hold Rating Amid Phase 3 Trial Failure and Financial Uncertainty - TipRanks
Opthea’s COAST Phase 3 Trial Fails to Meet Primary Endpoint, Raising Financial Concerns - TipRanks
Opthea COAST trial misses primary endpoint, enters talks with DFA Investors - TipRanks
Opthea reports phase 3 trial results for eye treatment - Investing.com
Promising Developments and Strong Financial Position Propel AbSci’s Growth Prospects - TipRanks
Opthea Limited Announces New Securities Quotation on ASX - TipRanks
Opthea Limited Reports Increased Losses Amid Clinical Advancements - TipRanks
Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment - TipRanks
Opthea reports mid-year financial results - Investing.com
Opthea Ltd completes key drug product campaign - Investing.com
Opthea Completes Key Phase 3 Trial Milestone in Wet AMD Treatment - TipRanks
Opthea Limited completes week 52 patient visits in the COAST trial - Ophthalmology Times
Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position - TipRanks
Opthea to Present at Oppenheimer Healthcare Conference - GlobeNewswire Inc.
OPTOpthea Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Is Opthea Limited (OPT) One of the Best ASX Stocks to Buy According to Hedge Funds? - Insider Monkey
Opthea Unveils Promising Wet AMD Therapy at Investor Day - TipRanks
Why Opthea (OPT) Is Among the Best Australian Stocks to Buy Now? - Yahoo Finance
Opthea Sets Key 2025 Investor Events to Showcase Breakthrough Wet AMD Treatment Sozinibercept - StockTitan
Opthea Limited Reports Earnings Results for the Half Year Ended December 31, 2024 - Marketscreener.com
Opthea to Present Phase 3 Trial Update at J.P. Morgan Healthcare Conference - TipRanks
Race Oncology bolsters leadership - The Australian
Opthea Limited Targets AMD Market with Sozinibercept - TipRanks
Opthea Appoints Kathy Connell to Board of Directors - The Manila Times
Opthea's Wet AMD Program Featured at Ophthalmology Events - The Manila Times
Opthea to Participate in November Investor Conferences - The Manila Times
Is Opthea Limited (OPT) the Penny Stock with the Biggest Upside Potential According to Analysts? - Yahoo Finance
Opthea Limited Adr (OPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10.28%
2.59%
자본화:
|
볼륨(24시간):